Robert K Hastings
Overview
Explore the profile of Robert K Hastings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gordon N, McGuigan E, Ondasova M, Knight J, Baxter L, Ott S, et al.
Biomark Res
. 2024 Nov;
12(1):133.
PMID: 39511596
Background And Aims: Several non-invasive tests for detecting bladder cancer (BC) are commercially available and are based on detecting small panels of BC-associated mutations and/or methylation changes in urine DNA....
2.
Fernandez-Garcia D, Nteliopoulos G, Hastings R, Rushton A, Page K, Allsopp R, et al.
Br J Cancer
. 2022 Sep;
127(10):1858-1864.
PMID: 36088510
Background: We report copy-number profiling by low-pass WGS (LP-WGS) in individual circulating tumour cells (CTCs) for guiding treatment in patients with metastatic breast cancer (MBC), comparing CTC results with mutations...
3.
Page K, Martinson L, Fernandez-Garcia D, Hills A, Gleason K, Gray M, et al.
JCO Precis Oncol
. 2021 Dec;
5.
PMID: 34849446
Purpose: We investigated the utility of the Oncomine Breast cfDNA Assay for detecting circulating tumor DNA (ctDNA) in women from a breast screening population, including healthy women with no abnormality...
4.
Sereno M, He Z, Smith C, Baena J, Das M, Hastings R, et al.
Histopathology
. 2020 Nov;
78(6):838-848.
PMID: 33155719
Aims: The decision to consider adjuvant chemotherapy (AC) for non-small cell lung cancer is currently governed by clinical stage. This study aims to assess other routinely collected pathological variables related...
5.
Eastley N, Sommer A, Ottolini B, Neumann R, Luo J, Hastings R, et al.
Int J Mol Sci
. 2020 Jul;
21(12).
PMID: 32599895
Soft tissue sarcomas (STS) are rare, malignant tumours with a generally poor prognosis. Our aim was to explore the potential of cell free DNA (cfDNA) and circulating tumour DNA (ctDNA)...
6.
Fernandez-Garcia D, Hills A, Page K, Hastings R, Toghill B, Goddard K, et al.
Breast Cancer Res
. 2019 Dec;
21(1):149.
PMID: 31856868
Background: Breast cancer (BC) is the most common cancer in women, and despite the introduction of new screening programmes, therapies and monitoring technologies, there is still a need to develop...
7.
Coombes R, Page K, Salari R, Hastings R, Armstrong A, Ahmed S, et al.
Clin Cancer Res
. 2019 Apr;
25(14):4255-4263.
PMID: 30992300
Purpose: Up to 30% of patients with breast cancer relapse after primary treatment. There are no sensitive and reliable tests to monitor these patients and detect distant metastases before overt...
8.
Eastley N, Ottolini B, Neumann R, Luo J, Hastings R, Khan I, et al.
Oncotarget
. 2018 Mar;
9(12):10549-10560.
PMID: 29535826
Following treatment 40% of soft tissue sarcoma (STS) patients suffer disease recurrence. In certain cancers circulating cell free DNA (cfDNA) and circulating tumour-derived DNA (ctDNA) characteristics correlate closely with disease...
9.
Page K, Guttery D, Fernandez-Garcia D, Hills A, Hastings R, Luo J, et al.
Clin Chem
. 2016 Dec;
63(2):532-541.
PMID: 27940449
Background: Breast cancer tissues are heterogeneous and show diverse somatic mutations and somatic copy number alterations (CNAs). We used a novel targeted next generation sequencing (NGS) panel to examine cell-free...
10.
Shaw J, Guttery D, Hills A, Fernandez-Garcia D, Page K, Rosales B, et al.
Clin Cancer Res
. 2016 Jun;
23(1):88-96.
PMID: 27334837
Purpose: The purpose of this study was to directly compare mutation profiles in multiple single circulating tumor cells (CTC) and cell-free DNA (cfDNA) isolated from the same blood samples taken...